$ARNA - Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
The companys advanced stage drug candidate includes the lorcaserin for the treatment of weight management, including weight loss and maintenance of weight loss. Its product in clinical development comprises APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension.
The companys preclinical development programs include APD334, an oral treatment for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis; and APD371 for the treatment of pain.
The company also researches and develops GPR119, a pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes, as well as temanogrel, nelotanserin, and earlier-stage programs. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Please keep (ARNA) Arena Pharmaceuticals, Inc.on your watch list for a price move above $8.96 - $9.01 on heavier than average daily trading volume of 16.19 million.
As of the close of trading on Friday (ARNA) Arena Pharmaceuticals, Inc. ended the week trading at $9.08 +0.26 or +3.32% on lighter than average upside trading volume of 10.0 million. Please note that this is not a buy recommendation please do your own due diligence or get help from a professional before trading.
By: Marlin Rolle
*** Please have a close look at the charts listed below ****